Key result
Early evolocumab in ACS deepens LDL-C lowering and accelerates attainment of stringent targets vs control.
Why the study?
Does early initiation of evolocumab improve LDL-C lowering and accelerate target attainment in patients with acute coronary syndrome?
Does early initiation of evolocumab improve LDL-C lowering and accelerate target attainment in patients with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
Early initiation of evolocumab in acute coronary syndrome patients accelerates the achievement of stringent LDL-C targets, which is critical for reducing recurrent events.
. Scores were similar, and no deterioration was seen with evolocumab compared with control. These findings indicate that adding early evolocumab to background therapy not only deepens LDL-C lowering but also accelerates attainment of stringent targets, a key objective in very-high-risk patients where time spent above goal is linked to recurrent events and worse outcomes.
No takes yet. Share an insight, caveat, or question.
Hack-Lyoung Kim (2026) studied this question. Early evolocumab added to background therapy in acute coronary syndrome deepens LDL-C lowering and accelerates attainment of stringent targets compared with control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: